• Lilly outlined 21 dermatology presentations scheduled for Oct. 8-11 at Fall Clinical 2026, with new data across EBGLYSS, Taltz, Zepbound.
• EBGLYSS posters will focus on durable disease control, less frequent maintenance dosing, reduced reliance on topical treatments in moderate-to-severe atopic dermatitis.
• TOGETHER-PsO analyses will assess tirzepatide added to ixekizumab in psoriasis with obesity, including biomarker readouts and cardiovascular risk factors.
• BRAVE-AA-PEDS updates will present longer-term outcomes for Olumiant in adolescents with severe alopecia areata, supporting pediatric expansion efforts.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eli Lilly and Company published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610050750PR_NEWS_USPR_____DE63096) on October 05, 2026, and is solely responsible for the information contained therein.